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ABSTRACT
Aim : To see the characteristics of Non Hodgkin’s Lymphoma patients in Jakarta. Methods: The retrospective design
was used in this research. Sample were Non Hodgkin Lymphoma patients who treated in Cipto Mangunkusumo
National Hospital and “Dharmais” National Cancer  Center Hospital during 2004-2005. Results: Seventy eight percent
of NHL patients were at the age of bellow sixty years old with male gender predominant (60.8%), stage I-II (68.97%)
and good performance status (ECOG 0-1, 86.67%). Based on exposure evaluation, eighty percent patients were
unknown. Out of 153 patients, 94 patients were treated  by CHOP regimen, only 51 patients who complete the minimal
six cycles of regimen. The response to treatment on this group were : complete remission (52.38%), partial remission
(26.19%), and minimal response (14.2%).
In the CHOP group of treatment, we reported that eighty percent of NHL patients were at the age of bellow sixty years
old with  early stage (stage I-II, 74.47%) and good performance status (ECOG 0-1, 93.3%). Also reported that ninety
percent patient had ≤ 1 extranodal involvement and normal LDH level (60%). Based on pathology results in CHOP
group of treatment, fifty three percent patients were Diffuse Large B Cell (DLBCL) NHL.
Conclusion: NHL patients characteristics in Jakarta predominantly were bellow sixty years old with male gender, early
stage and good performance status. Based on CHOP group of treatment, we reported also a bellow sixty years old
patients with early stage and good performance status. Fifty percent patients in the CHOP group of treatment had
complete remission after minimal six cycle of chemotherapy
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ABSTRAK
Tujuan: Melihat karakteristik pasien Limfoma Non Hodgkin di Jakarta. Metode: studi retrospektif. Sampel adalah pasien
Limfoma Non Hodgkin yang berobat di RS Cipto Mangunkusumo dan RSK “Dharmais” antara tahun 2004-2005.
Hasil: Tujuh puluh delapan persen pasien memiliki usia kurang dari 60 tahun dengan gambaran mayoritas jenis kelamin
laki-laki, stadium awal (60,8%) dan status performans yang baik (ECOG 0-1; 86,67%). Berdasarkan evaluasi terhadap
paparan, didapati delapan puluh persen pasien tidak diketahui paparannya.
Dari 153 pasien, 94 pasien diobati dengan kemoterapi regimen CHOP, namun hanya 51 pasien yang menyelesaikan
minimal 6 siklus kemoterapi. Dilaporkan juga respon terhadap terapi adalah: remisi komplit (52,38%), remisi parsial
(26,19%) dan respon minimal (14,2%).
Pada kelompok pasien yang diobati dengan regimen kemoterapi CHOP, dilaporkan bahwa delapan puluh persen pasien
berusia di bawah 60 tahun, memiliki stadium awal (stadium I-II; 74,47%) dan status performmans yang baik (ECOG I-II;
93,3%). Juga dilaporkan bahwa sembilan puluh persen pasien memiliki  ≤ 1 keterlibatan ekstranodal dan kadar LDH
normal (60%). Berdasarkan hasil patologi, dilaporkan lima puluh persen pasien memiliki gambaran  patologi DLBCL
(Diffuse Large B Cell L).
Kesimpulan 
Sebagian besar pasien Limfoma Non Hodgkin di Jakarta memiliki karakteristik klinis: usia di bawah 60 tahun dengan
jenis kelamin laki-laki, stadium awal dan status performans yang baik. Pada kelompok pasien yang menjalani
kemoterapi regimen CHOP juga dilaporkan karakteristik klinis yang sama. Lima puluh persen pasien yang menjalani
kemoterapi regimen CHOP mencapai respon komplit setelah menjalani minimal 6 siklus kemoterapi.
Kata kunci : Limfoma Non Hodgkin, Performa studi, remisi
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INTRODUCTION
The term of lymphoma describes a heterogeneousgroup of malignancies, which are divided into two
large groups of neoplasms, namely Non Hodgkin’s
Lymphoma and Hodgkin disease. About 90% of all
malignant lymphomas are Non Hodgkin’s Lymphomas
(NHL).1-3
The incidence of NHL had increased dramatically
since 1970 and continues to raise at the rate of 5-10%
each year. It reached five most frequent malignant
diseases in America with 12-15 cases per 100,000 people,
accounting for 4% of all malignancies.4 National Cancer
Institute, in 1996, reported the incidence of NHL in
America was 15.5 per 100,000 people. In Indonesia, NHL
along with Hodgkin disease and leukemia ranks as the
sixth most frequent diseases. Along with the increase of
NHL incidence, its mortality rates continues to increase.5
In 1997, NHL was reported as a major malignant cause of
death of male patients at the age 29-30 years. In the year
2000, it was reported in America that there were 54,900
new cases and 26,100 of them died. In 2001, NHL was
found as the fourth leading cause of cancer deaths.6
There is still no explanation for the increasing incidence
of NHL. Close association between AIDS and NHL may
highlight the uncertain link between NHL and infection.7-9
We still need to conduct further research to look for
possible explanation for the increasing number of the
NHL’s incidence. 
Surveillance Epidemiology and End Result (SEER) in
United States of America reports that the median age at
diagnosis for NHL is 67 years old and rarely happens in
children or adolescence. However, it can be found at all
age.5,10,11 NHL is found more frequent  in male with the
incidence 19 per 100,000 people than in female, 12 per
100,000 people.11
Non-Hodgkin’s Lymphoma (NHL) originates from the
lymphoid tissues. It represents a group of primary
lymphocyte malignancy, which evolves from B cell, T cell
or Natural Killer (NK) cell within the lymphatic system.
This group of disease shows different varieties of
histological appearances, clinical pictures, responses to
therapy and prognosis. 1-3
The diagnosis of NHL based on history, physical
examination, laboratory studies and additional
investigations. However, different varieties of NHL clinical
manifestations have made early diagnosis difficult to
make. Most patients are more likely to be asymptomatic,
especially in indolent NHL.11 Therefore, the diagnosis of
NHL relies on pathological confirmation following
appropriate tissue biopsy. In addition to histopathological
examination, recent studies has demonstrated the
significance of using modern techniques such as
immunohistochemistry and immunophenotyping, which
are found to be sensitive and specific in diagnosis and
classification of NHL.12,13 Nevertheless, more research is
needed to attribute the significance of these modern
techniques in the making if NHL diagnosis. 
Twenty-one days CHOP regimen has been the
standard treatment for patients with NHL and should be
given every three weeks for 3-6 cycles. Some literatures
stated that treatment can be given in two weeks (fourteen
days) if necessary.14 Delay of treatment is allowed for one
week, nonetheless, it is not stated regarding the
maximum number of treatment delay for a patient that
still can give good result. Subsequently, literatures stated
that if the treatment were delivered accurately, a
complete remission would reach 80% of all patients given
CHOP regimen. Salvage regimen is given to the patients
experiencing relapse.15 Meanwhile, for the patients
proved unresponsive or estimated to be less responsive,
some centers would choose to perform bone marrow
transplant. Recent studies have reported better results in
the addition of rituximab to the CHOP regimen.11,16,17
Objectives: There are no sufficient and reliable data
regarding epidemiologic study in NHL patients receiving
CHOP regimen in Indonesia. Meanwhile, the need of
preliminary study in this field is essential to provide
valuable reports for further research. 
Therefore, the objective of the study is to see the
epidemiology of Non Hodgkin’s Lymphoma in Indonesia,
particularly in Jakarta.
MATERIAL AND METHODS
Our epidemiological study was conducted in Jakarta,
Indonesia. The method that used was a retrospective
research in NHL patients receiving chemotherapy
treatments in Cipto Mangunkusumo National Hospital
and “Dharmais” Cancer Hospital during 2004-2005.
RESULTS
Basic Characteristics
The NHL demographic data in Indonesia is presented
in table 1. It is shown that 117 patients (78%) of 153 NHL
patients in our study were at the age of less than sixty
years old. The table also shows a higher incidence on
male than female. 
There were no specific preferences among patients
race. Of 153 patients, 35 patients (22.9%) were each
Javanese and Betawi, 23 patients (15%) were Sundanese, 7
patients were Batak (4.6%), 6 patients (3.9%) were
Chinese, 5 patients (3.3%) were Padang and 42 remaining
patients (27.5%) were classified in Others. Exposure also
seems to show no specific preferences. One hundred and
twenty eight patients (83.8%) were having NHL without
unknown exposures. However, 17 patients (11%) were
exposed to cigarette consumption, 3 patients (2%) were
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exposed to chemicals, 3 patients (2%) were exposed to
ultraviolet (sunlight), 1 patient (0.7%) was exposed to
radiation (non UV) and 1 patient (0.7%) was exposed hair
toning. Our study also shows that 123 patients (80.4%)
had unknown family history of cancer, 29 patients (19%)
had no family history of cancer and only one patient (7%)
had family history of cancer.
Ninety-one patients (86.67%) showed ECOG
performance status of 0 and 1, while the remaining 14
patients (13.33%) showed Eastern Cooperative Oncology
Group (ECOG) performance status of 2, 3 and 4.
Approximately more than half of all patients were at early
stage I – II (68.97%), and had normal level of LDH
(59.52%).
Clinical Characteristic
Of 153 patients, 59 patients (38.56%) have not been
treated. Ten patients (6.54%) each have entered first and
second cycle of CHOP treatment. Eleven patients (7.19%)
have entered the third cycle, 4 patients (2.61%) have
entered the fourth cycle, 8 patients (5.23%) have entered
the fifth cycle, 42 patients (27.45%) have entered the sixth
cycle, 2 patients (1.31%) have entered the seventh cycle, 6
patients (3.92%) have entered the eighth cycle.
Out of 153 patients, 51 patients were treated with
minimally six cycles of CHOP with response to treatment
showed in table 3.
The response to treatment of this group shows 22
patients with complete remission (52.38%), 11 patients
with partial remission (26.19%), and six patients (14.29%)
with minimal response. Three patients (7.14%) were
progressive during treatment and there were nine
patients (17. 65%) with unavailable data. We also tried to
compare the feature between CHOP and non CHOP
group of chemotherapy regimen. 
In comparison between patients receiving CHOP as
chemotherapy regimen and patients not receiving CHOP
as chemotherapy regimen, the majorities in both groups
were at age less than 60 years old, had ECOG
performance status score 0 and 1, had normal level of
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Table 1: Basic characteristics
Characteristic N %
Age
< 60 years old 117 78
> 60 years old 33 22
Sex
Male 93 60.8
Female 60 39.2
Race
Java 35 22.9
Sundanese 23 15.0
Batak 7 4.6
Padang 5 3.3
Betawi 35 22.9
Chinese 6 3.9
Others 42 27.5
Exposure
Chemicals 3 2
Cigarette 17 11
Radiation (non UV) 1 0.7
Ultraviolet (sunlight) 3 2
Hair Toning 1 0.7
Unknown 128 83.8
Family History of Cancer
Yes 1 7
No 29 19
Unknown 123 80.4
ECOG
0 & 1 91 86.67
2,3 & 4 14 13.33
Staging
I √ II  100 68.97
III, IV 44 30.34
Relapse 1 0.67
LDH
Normal  50 59.52
High 34 40.48
Table 2: Frequency of CHOP treatment
Frequency of treatment N %
0 59 38.56
1 10 6.54
2 10 6.54
3 11 7.19
4 4 2.61
5 8 5.23
6 42 27.45
7 2 1.31
8 6 3.92
13 1 0.65
Total 153 100.00
Table 3: Treatment response of minimally 6 cycles CHOP
Type of response Number of treatment
Frequency %
Complete Response 22 52.38
Partial Response 11 26.19
Minimal Response 6 14.29
Relapse 3 7.14
Total 42 100.00
* Unavailable data: nine patients
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LDH, had less than one extra nodal involvement and were
stages I or II. Table 4 shows that 14 patients not receiving
CHOP (13.33%) have ECOG score two, three and four.
Moreover, on patients receiving minimally 6 cycles of
CHOP, only three patients (6.67%) have ECOG score
above one.
The elevated LDH was identified as a negative
prognostic factor and normal LDH shows good prognosis.
There are 34 patients (40.47%) with high level of LDH on
patients who were not treated with CHOP and only 12
patients (40%) with high level of LDH on patients who
were treated with 6 cycles of CHOP chemotherapy.
However, there are 50 patients (59.52%) with normal level
of LDH in the group who were not receiving CHOP and
there are 18 patients (60%) in the group who were
receiving CHOP.
At first we concluded that most patients were
admitted in advanced stage, thus, the treatment was
showing poor response. Nevertheless, it shows only 44
patients out of 145 patients not receiving CHOP (30.35%)
who were advanced stages (III or IV). In the group of
patients treated with 6 cycles of CHOP, only 12 patients
(25.53%) were admitted in stages III or IV. This does not
support our conclusion.
Based on pathology result, most cases from patients
treated with or without CHOP are diffuse large B cell NHL.
Other form with frequent incidence after the diffuse large
B cell NHL is large B cell NHL.
Immunohistochemistry study in all patients and
patients treated with 6 cycles of CHOP shows that there
are more than 60% patients have aggressive lymphoma. It
is then considered that this factor reasons the patients’
poor response to CHOP regiment therapy. The causal
relationship between them is still yet to be explained,
thus, further research is needed to elaborate the relation
between aggressive lymphoma with poor response to
CHOP regimen.
Three multicenter studies consisting of ECOG (Eastern
Cooperative Oncology Group), SWOG (Southwest
Oncology Group), and GELA (Groupe d’Etude des.
Lymphomes de l’Adulte) each showed complete
response and or partial response after 8 cycles of CHOP
61%, 73%, 89% respectively. GELA study also showed
complete and partial response subsequently using these
regimen; COP (44%&36%), Mbacod (48% & 34%), Pro
MACE/Cytabom (56%&31%), and Macod B (51%&32%).
Study conducted in France in 2003 which compared
the use of CHOP and more aggressive ACBVP
(doxorubicin, cyclophosphamide, vindesine, bleomycin,
prednisone) showed that ACBVP was more superior than
CHOP as first line regimen for aggressive lymphoma or
poor prognosis case, based on event-free survival (39%
vs. 29%) and overall survival (46% vs. 38%), though with
much higher level of toxicity. Meanwhile, in complete
response patients, the use of ACBVP has quite similar
result with use of CHOP (58% vs. 56%).
CONCLUSION
NHL patients characteristics in Jakarta predominantly
were bellow sixty years old with male gender, early stage
and good performance status. Based on CHOP group of
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Table 4: Clinical and laboratory feature of patient with and without CHOP
as chemotherapy regimen
Variables Results 
Non CHOP (%) CHOP (%)
Age
• < 60 years old 117 (78) 41 (80.4)  
• > 60 years old 33 (22) 10 (19.6)  
ECOG     
• 0 & 1  91 (86.67) 42 (93.3)  
• 2, 3 & 4  14 (13.33) 3 (6.67)  
LDH     
• Normal  50 (59.52) 18 (60)  
• High  34 (40.48) 12 (40)  
Extra nodal Involvement     
• < 1 locations  136 (89.47) 46 (90.2)
• > 1 locations 16 (10.53) 5 (9.8)
Stadium 
• I or II 100 (68.97) 35 (74.47)
• III or IV 44 (30.34) 12 (25.53)
• Relapse 1 (0.67) 0 
Pathology Result
• Diffuse Large B Cell NHL* 41 (45.6) 16 (53.33)
• Large Centroblastic B Cell NHL 4 (4.44) 1 (3.33)
• Large B Cell Lymphoma, Variant 
T Cell Rich* 1 (1.11) 1 (3.33)
• Large B Cell NHL* 9 (10) 5 (16.67)
• Diffuse Large B Cell Lymphoma 
Var. Centroblastic* 2 (2.22) 0
• B Cell Lymphoma* 3 (3.33) 1 (3.33)
• Mantle Cell Lymphoma, Diffuse Large 
B Cell^ 1 (1.11) 1 (3.33)
• Mantle Cell Lymphoma^ 1 (1.11) 1 (3,33)
• Blastoid Mantle Cell Lymphoma^ 1 (1.11) 0
• Follicular B Cell# 4 (4.44) 1 (3,33)
• Diffuse Follicle Center Lymphoma 2 (2.22) 0
• Follicular Lymphoma Grade 2# 1 (1.11) 0
• Follicular Lymphoma Grade 1# 2 (2.22) 1 (3.33)
• T/NK Cell Lymphoma Nasal Type 1 (1.11) 0
• NK/TCL Lymphoma+ 6 (6.67) 2 (6.67)
• T Cell NHL 6 (6.67) 0
• Small Lymphocytic NHL 2 (2.22) 0
• Small B Cell NHL 1 (1.11) 0
• Monocytoid B Cell Lymphoma 1 (1.11) 0
• Inflammation reaction 1 (1.11) 0
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treatment, we reported also a bellow sixty years old
patients with early stage and good performance status.
Fifty percent patients in the CHOP group of treatment had
complete remission after minimal six cycle of
chemotherapy
We recommend for a better research design to be able
to identify all prognostic factors, evaluate the treatment
until the fourth cycle and immediately substitute the
CHOP regimen therapy on patients who do not show
complete remission. This is due to the correlating data
that showed more than 60% of patients have high
aggressive lymphoma, that they would need much
stronger and more aggressive regiment. v
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